FDA Clears Akili’s EndeavorRx for Children with ADHD
The U.S. Food and Drug Administration granted clearance for Akili’s EndeavorRx as a prescription treatment for children with attention deficit hyperactivity disorder (ADHD).
About Business Wire
This author has yet to write their bio.Meanwhile lets just say that we are proud Business Wire contributed a whooping 625 entries.
Entries by Business Wire
FDA Approves Merck’s GARDASIL 9 for the Prevention of Certain HPV-Related Head and Neck Cancers
The U.S. Food and Drug Administration approved an expanded indication for Merck’s GARDASIL 9 for the prevention of oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58.
MJH Life Sciences Launches Medical World News
MJH Life Sciences officially launched Medical World News, a first-of-its-kind 24-hour news program offering insights on the latest news in health care.
FDA approves Tecentriq-Avastin combo for liver cancer
The U.S. Food and Drug Administration approved Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) for the treatment of people with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.
FDA Approves Dupixent for Children with Moderate-to-Severe Atopic Dermatitis
The U.S. Food and Drug Administration approved Dupixent (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis.
Klick Health Study in Nature Says New Homeostasis Model Could Help Doctors Detect Chronic Disease Early
New Klick Health research published in Nature Digital Medicine says physicians could get a more comprehensive view of their patients’ health – and even help predict chronic disease early by assessing the interdependence of their health indicators and the body’s homeostasis system that controls them.
U.S. FDA Approves Takeda’s Alunbrig as First-Line Treatment Option for Rare Form of Lung Cancer
The U.S. Food and Drug Administration approved Takeda Pharmaceutical Company Limited’s Alunbrig (brigatinib) for adult patients with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer as detected by an FDA-approved test.
W2O Reports 18th Consecutive Year of Double-Digit Growth Surpassing $220 Million in Revenue in 2019
W2O reported 2019 revenue increased by 26 percent to $223 million from $177 million in 2018 and improved operating profit.
Veeva Announces Vault Site Connect to Automate Information Sharing in Clinical Trials
Veeva Systems announced Veeva Vault Site Connect, a new application that connects sponsors and clinical research sites during trials.
Veeva Announces MyVeeva to Enable Patient-Centric Clinical Trials
Veeva Systems announced MyVeeva, a new application for clinical research sites.